Clinilabs Strengthens Executive Leadership with the Appointments of Dr. Bob Dagher as Chief Medical Officer and Dr. Waqar Ahmed Siddiqui as Principal Investigator
Clinilabs LLC, a global full-service contract research organization (CRO) specializing in the development of therapies for central nervous system (CNS) disorders, has announced the appointments of Bob Dagher, M.D., as Chief Medical Officer (CMO) and Waqar Ahmed Siddiqui, M.D., as Principal Investigator at the company’s Clinical Research Unit (CRU) in Eatontown, New Jersey. The strategic leadership additions reinforce Clinilabs’ commitment to expanding its medical expertise and strengthening its ability to support pharmaceutical, biotechnology, and medical device companies developing innovative treatments for neurological, psychiatric, substance use, and rare CNS disorders.
The appointments come at a time when demand for specialized clinical research capabilities continues to grow, particularly in neuroscience, where complex disease biology and evolving regulatory expectations require experienced scientific leadership throughout every stage of clinical development. By adding two accomplished physician leaders with extensive backgrounds in clinical medicine, drug development, regulatory strategy, and patient care, Clinilabs aims to further enhance its integrated development platform and provide sponsors with greater expertise as they advance novel therapies from early research through regulatory approval.
Strengthening Leadership to Support CNS Drug Development
Central nervous system disorders remain among the most challenging therapeutic areas in medicine. Diseases such as depression, schizophrenia, Alzheimer’s disease, Parkinson’s disease, epilepsy, multiple sclerosis, amyotrophic lateral sclerosis (ALS), substance use disorders, and numerous rare neurological conditions continue to present significant unmet medical needs despite decades of scientific progress.
Developing treatments for these conditions requires highly specialized expertise in neuroscience, clinical trial design, biomarker development, patient recruitment, safety monitoring, regulatory interactions, and statistical evaluation.
Clinilabs has built its reputation by focusing exclusively on CNS drug and medical device development, providing sponsors with comprehensive clinical research services that span the entire product development lifecycle.
The appointments of Dr. Dagher and Dr. Siddiqui further strengthen the company’s ability to deliver scientific leadership across these increasingly sophisticated development programs.
Complementary Leadership Experience
According to Clinilabs, the two new physician leaders bring highly complementary expertise that spans both strategic drug development and hands-on clinical research execution.
As Chief Medical Officer, Dr. Dagher will oversee medical and scientific leadership across the organization, helping shape clinical development strategies while supporting interactions with regulatory agencies and industry sponsors.
Meanwhile, Dr. Siddiqui will oversee research activities at Clinilabs’ Eatontown Clinical Research Unit, leading the execution of clinical studies while ensuring high standards of patient care, protocol compliance, and operational excellence.
Together, the two leaders will support pharmaceutical, biotechnology, and medical device companies developing therapies targeting psychiatric disorders, neurological diseases, substance use disorders, and rare CNS conditions.
Their combined expertise is expected to strengthen both the strategic planning and day-to-day execution of complex clinical research programs.
Supporting Sponsors Across Every Development Stage
Modern CNS drug development often extends over many years, beginning with laboratory research before progressing through first-in-human studies, multiple phases of clinical testing, regulatory review, and eventual commercialization.
Each stage presents unique scientific and operational challenges.
Early-phase studies require careful safety monitoring and dose selection.
Later-stage clinical trials demand robust study design, patient enrollment strategies, endpoint selection, statistical planning, and regulatory coordination.
Clinilabs provides integrated support across these development stages, helping sponsors navigate increasingly complex research programs while maintaining high standards of scientific quality.
The addition of experienced medical leaders further enhances the company’s ability to guide sponsors through these critical milestones.
Commitment to Scientific Excellence
Eileen McAuley, Chief Operating Officer of Clinilabs, emphasized that the organization has built longstanding relationships with pharmaceutical and biotechnology sponsors through its combination of scientific expertise, medical leadership, and operational excellence.
She noted that the company has consistently demonstrated the ability to execute clinical programs ranging from first-in-human studies to successful regulatory approvals.
According to McAuley, the appointments of Dr. Dagher and Dr. Siddiqui significantly expand the company’s capabilities by bringing together expertise in strategic drug development, regulatory science, clinical research, and patient care.
She explained that their combined experience will help sponsors navigate increasingly complex development programs while supporting efforts to bring innovative therapies to patients with significant unmet medical needs.
Dr. Bob Dagher Appointed Chief Medical Officer
As Clinilabs’ newly appointed Chief Medical Officer, Dr. Bob Dagher assumes responsibility for providing strategic medical leadership across the organization.
His appointment brings more than two decades of executive experience spanning clinical development, medical affairs, regulatory strategy, and neuroscience research.
Throughout his career, Dr. Dagher has held senior leadership positions across multiple biotechnology companies focused on developing therapies for neurological, psychiatric, immunological, and rare diseases.
His broad experience includes overseeing programs from preclinical planning through first-in-human studies, Phase 1, Phase 2, and Phase 3 clinical trials, as well as supporting regulatory submissions for product approval.
Such experience is particularly valuable within CNS drug development, where regulatory expectations and clinical trial complexity continue to evolve.
Experience Leading Biotechnology Development Programs
Before joining Clinilabs, Dr. Dagher served as Chief Medical Officer for four biotechnology companies.
Across these organizations, he directed multiple clinical development programs involving both small molecules and biologic therapies.
His work has encompassed therapeutic areas including mood disorders, psychotic disorders, neurodegenerative diseases, multiple sclerosis, amyotrophic lateral sclerosis, and several rare CNS conditions.
In addition to clinical development, Dr. Dagher has accumulated extensive experience in medical affairs, regulatory interactions, and strategic planning.
He has guided development programs through biologics license application (BLA) submissions and numerous interactions with regulatory authorities.
His familiarity with regulatory strategy is expected to benefit Clinilabs’ clients as they navigate approval pathways for innovative CNS therapies.
Providing Strategic Medical Leadership
In his new position, Dr. Dagher will play a central role in designing clinical development strategies for sponsor programs.
His responsibilities will include supporting protocol development, medical oversight, safety evaluation, regulatory planning, and scientific consultation.
He will also collaborate closely with sponsors seeking to optimize clinical trial design while ensuring programs meet evolving regulatory requirements.
Given the increasing complexity of neuroscience research, experienced medical leadership has become essential for successfully advancing promising therapies through development.
Dr. Dagher’s extensive background across multiple neurological and psychiatric indications positions him to provide valuable guidance throughout these processes.
Dr. Waqar Ahmed Siddiqui Joins as Principal Investigator
Clinilabs also announced the appointment of Dr. Waqar Ahmed Siddiqui as Principal Investigator at the company’s Eatontown Clinical Research Unit.
Dr. Siddiqui brings extensive clinical experience in psychiatry, behavioral health leadership, and clinical research.
As Principal Investigator, he will oversee the conduct of clinical studies performed at the research facility while ensuring participant safety, protocol compliance, and data integrity.
His role will involve direct interaction with research participants, study teams, sponsors, and regulatory authorities to ensure successful execution of clinical programs.
Because CNS clinical trials often involve vulnerable patient populations and complex neurological assessments, experienced physician investigators play an especially important role in maintaining study quality.
Extensive Psychiatry and Clinical Research Experience
Dr. Siddiqui is a board-certified psychiatrist with a distinguished career spanning clinical practice, hospital leadership, and research.
Throughout his career, he has served as Principal Investigator for numerous clinical trials evaluating therapies for psychiatric, neurological, and musculoskeletal disorders.
His experience includes overseeing both inpatient and outpatient behavioral health programs while participating in research designed to improve treatment options for patients with serious mental illness.
Most recently, he served as Clinical Director and Chief Medical Officer of South Beach State Psychiatric Hospital in New York City.
In that position, he supervised psychiatric services while leading clinical operations within one of the region’s major behavioral healthcare institutions.
Prior to this role, he served as Chairman of the Department of Psychiatry at Hoboken University Medical Center and as Medical Director of the Behavioral Health Center at JFK Medical Center in New Jersey.
These leadership positions provided extensive experience managing multidisciplinary healthcare teams while maintaining a strong focus on patient-centered care.
Enhancing Clinical Research Operations
At Clinilabs, Dr. Siddiqui will oversee execution of clinical research projects conducted at the Eatontown Clinical Research Unit.
His responsibilities include ensuring studies are conducted according to Good Clinical Practice (GCP), regulatory requirements, and approved study protocols.
He will also work closely with sponsors to facilitate efficient study enrollment, patient monitoring, safety assessments, and data collection.
His background as both a practicing psychiatrist and experienced clinical investigator enables him to balance scientific rigor with compassionate patient care, an important consideration in studies involving psychiatric and neurological disorders.
Addressing Growing Demand for CNS Research
Interest in developing therapies for neurological and psychiatric diseases has grown substantially in recent years.
Advances in neuroscience, genetics, neuroimaging, artificial intelligence, and biomarker discovery are creating new opportunities to develop treatments targeting diseases that previously lacked effective therapeutic options.
At the same time, regulatory expectations for demonstrating safety and efficacy have become increasingly sophisticated.
Contract research organizations with specialized neuroscience expertise therefore play a critical role in helping sponsors efficiently navigate complex development programs.
Clinilabs’ continued investment in experienced physician leadership reflects its commitment to meeting this growing demand while maintaining high scientific and operational standards.
Positioned for Continued Growth
The appointments of Dr. Bob Dagher as Chief Medical Officer and Dr. Waqar Ahmed Siddiqui as Principal Investigator represent an important step in Clinilabs’ ongoing strategy to strengthen its medical and scientific leadership. Together, the two physician leaders bring decades of combined experience spanning executive biotechnology leadership, regulatory strategy, psychiatry, behavioral health, and clinical research.
As pharmaceutical, biotechnology, and medical device companies continue developing innovative therapies for neurological, psychiatric, substance use, and rare CNS disorders, Clinilabs aims to provide the specialized expertise necessary to support successful clinical development. By combining strategic medical oversight with experienced clinical research execution, the company is well positioned to help sponsors navigate increasingly complex development pathways while accelerating the delivery of innovative treatments to patients living with challenging central nervous system diseases.
About Clinilabs
Clinilabs is a global, full-service contract research organization dedicated exclusively to CNS drug, device, and technology development, combining deep scientific expertise, proven processes, advanced technology, and a global footprint across North America, Europe, and beyond to manage Phase 1-4 trials that accelerate treatments for psychiatric, neurological, and substance use disorders, as well as rare and ultra-rare CNS diseases. For more information, visit clinilabs.com.